49LOW

PAR

PARA BIO FPO [PAR]
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.2570 +0.8%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical58
Catalyst67
Sentiment50
Fundamental48
Momentum46
Risk Gate50
Get alerts when PAR's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track PAR — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Drifting lower — down 4.8% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.10, so it's outpacing the pack
  • Low cash runway (2 quarters) - dilution risk
  • Very high P/S ratio (13689.5x)
  • Strong revenue growth (+51%)
  • EPS estimates revised downward (-6pts)
  • Near 52-week low (8% of range)
  • Revenue declined -290% YoY
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +51% — the top line is moving in the right direction
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.32%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about PAR
"What's driving PAR's score?" "How does PAR compare to peers?" "Key risks for PAR?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

HIGH Hong Kong Site Activated for Phase 3 OA Study
NONE Application for quotation of securities - PAR
NONE Appendix 4D and Half Year Report
NONE Change of Director's Interest Notice

Recent ASX Announcements

2026-03-19 Hong Kong Site Activated for Phase 3 OA Study
2026-03-16 Application for quotation of securities - PAR
2026-02-26 Appendix 4D and Half Year Report PRICE SENSITIVE
2026-02-23 Change of Director's Interest Notice
2026-02-23 Change of Director's Interest Notice

Key Metrics

$115.7M
Market Cap
881K
Avg Volume
0.9x
Vol Ratio
$0.24 — $0.48
52-Week Range
0.4%
Short Interest
N/A
Cash Runway
-180.2%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 85%
LLeader vs LaggardlaggardRS: -5
IInstitutional SponsorshipweakInst: 6%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #40 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:PAR vs ATXPAR vs PNVPAR vs IMM
Scout Pro — Deeper Analysis for PAR
Try Pro free for 30 days
Share this analysis

Track PAR and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required